Cellestia Biotech AG (Cellestia) is proud to announce its selection for a CHF 2 million grant from the Swiss Innovation Agency, Innosuisse, as part of their Start- up Innovation project to advance to clinical Proof of Concept a first-in-class therapy for prevention of Graft vs Host Disease (GvHD).

The project aims at developing CB-103 as first-in-class drug to prevent GvHD in allogeneic- Hematopoetic Stem Cell Transplant (HSCT) patients. With this novel approach, Cellestia envisions a transformative shift in the management of GvHD from treatment to prevention.

“We extend our sincere thanks to Innosuisse for recognizing the potential of CB-103 in enhancingthe lives of patients grappling with GvHD” said Raj Lehal, CEO of Cellestia.